Building on complementary mechanisms between cancer and fibrosis

Our Pipeline

iOnctura’s pipeline contains an exquisitely selective PI3Kδ small molecule inhibitor which has just entered a phase I clinical trial in solid tumours, a second generation selective ATX small molecule inhibitor that is in IND enabling studies and an early preclinical phase anti-CD73 antibody program.

our current projects

Pipeline

–

WHO WE ARE

Catherine Pickering, CEO

Catherine holds a PhD in Medicinal Chemistry from The Institute of Cancer Research, London and an MBA from Henley Management College, UK. She is an experienced deal maker with broad transaction experience including licensing (in- and out licensing, option deals, and strategic collaborations) and M&A.

Lars van der Veen, COO

Lars holds a PhD in homogeneous catalysis (cum laude) from the University of Amsterdam. He is an experienced project and alliance manager with demonstrated leadership in pre-clinical and clinical development. He has managed >25 alliances for in-licensed and out-licensed products of both biologics and small molecules, driving governance, delivery of results and issue resolution.

Zoë Johnson,
CSO

Zoë holds a PhD in Pharmacology from King's College London, UK. Zoë has more than 15 years of experience in the biopharmaceutical industry in the UK and Europe where she has worked across a range of therapy areas including oncology, autoimmune & inflammatory diseases and allergy.

Michael Lahn, CMO

Michael holds a MD in Medical Microbiology from the University of Mainz. He has over 20 years’ experience in oncology clinical development in the pharmaceutical industry, where he was responsible for the development of multiple molecules through early and late clinical development.

MEET THE TEAM

iOnctura exercises exclusive global option to license two of Cancer Research UK’s projects

iOnctura SA is delighted to announce today that it has exercised its exclusive global option to license two of Cancer Research UK’s projects, which are the result of a successful strategic alliance programme with CRUK-Therapeutic Discovery Labs (TDL). Under the terms of the licence agreements iOnctura will be solely responsible for the development and commercialisation … Continue reading “iOnctura exercises exclusive global option to license two of Cancer Research UK’s projects”

iOnctura Expands its Clinical Advisory Board

Geneva, Switzerland, 4th February 2020: iOnctura SA, a clinical stage biopharmaceutical company, developing a pipeline of next generation molecules targeting cancer and fibrosis, announces the addition of new members to its Clinical Advisory Board (CAB) with the appointment of Dr. Hendrik-Tobias Arkenau, Executive Medical Director, Sarah Cannon Research Institute, UK, and Dr. Jordi Rodón Ahnert, … Continue reading “iOnctura Expands its Clinical Advisory Board”